
About ApiJect
ApiJect is a Healthcare company based in Stamford (United States) founded in 2015 by Marc Koska and Jay Walker. Medicine injectors are manufactured by ApiJect for medical applications. ApiJect has raised $111 million across 2 funding rounds from investors including Royalty Pharma, Jefferies and DFC. Its chief executive, as recorded, is Jay Walker. ApiJect offers products and services including Blow-Fill-Seal Container, Apiject Platform, and Prefilled Injector. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its legal entity is Apiject Systems, Corp. Its competitors include Exela Pharma, August Bioservices and INCOG BioPharma Services; 3 of its 3 listed competitors have raised funding.
Company details
ApiJect manufacturer of medicine injectors, focusing on providing healthcare solutions, biopharma outsourcing, cdmo, small molecules peptides, formulation, and injectibles. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Stamford, United States
- Founders Marc Koska, Jay Walker
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website apiject.com
- Social LinkedIn X Facebook YouTube
- Legal Name Apiject Systems, Corp.
- Total Equity Funding$111M (USD)
in 2 rounds
- Latest Funding Round$111M (USD), Series D
Apr 2022
- InvestorsRoyalty Pharma
& 2 more
Products & Services of ApiJect
ApiJect offers a comprehensive portfolio of products and services, including Blow-Fill-Seal Container, Apiject Platform, and Prefilled Injector.
Aseptic container for prefilled injections ensuring safety and sterility.
Platform simplifying injections for pharmaceuticals and global health use.
Device enabling easy administration by non-professionals in various settings.
Apps and channels of ApiJect
its YouTube channel ApiJect Systems, Corp. has 2.62K subscribers and 30 videos.
Videos from ApiJect
The most watched videos on ApiJect's YouTube channel, ApiJect Systems, Corp. (2.62K subscribers). Click a video to play it here.
More on ApiJect Systems, Corp..
Funding Insights of ApiJect
ApiJect has successfully raised a total of $111M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $111 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $111M
- Total Rounds 2
- Last Round Series D β $111M
- First Round $590M
(Nov 2020)
- Investors Count 3
All 2 funding rounds of ApiJect with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $111M | Series D | β | Royalty Pharma, Jefferies | β |
| Nov 2020 | $590M | Debt – Conventional | β | β |
3 investors in total: 3 institutional.
Investors in ApiJect
ApiJect has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Royalty Pharma, Jefferies and DFC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in marketed and late-stage biopharmaceutical companies. | 1996 | royaltypharma.com | New York, United States | |
Government agency supporting the development of SMEs | 2019 | dfc.gov | ||
Merger and acquisitions advisory services are provided across multiple sectors. | 1962 | jefferies.com | New York, United States |
Investor details for ApiJect
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ApiJect
34 people are tracked at ApiJect (22 in leadership, 12 in team).
| Name | Role | Group |
|---|---|---|
Marc Koska | Co-Founder & Head of Product | Leadership |
Jay Walker | Co-Founder & CEO | Leadership |
Peter Stone | EVP & Global Head of M&A | Leadership |
Ed Kelley | Chief Global Health Officer | Leadership |
Bo Kowalczyk | Chief Commercial Officer, ApiJect | Leadership |
Michael Buzecky | Senior Director Process Development & Packaging | Leadership |
Philip Tull | Vp, Government Projects And Government Contracts | Leadership |
Josh Myers | Vp, Distributed Manufacturing & Supply Chain | Leadership |
Kelly Wong Mba | Project Director | Leadership |
Christian Eichhorn Pe | Vice President, Process Development And Packaging | Leadership |
Paul Rutter | Senior Vice President Clinical Affairs | Leadership |
Lauren Greenberg | Vice President, Device Development | Leadership |
Stephanie Summe | Senior Director Device Development | Leadership |
Molly Weaver | Chief Technology Officer | Leadership |
Magdalena Fincham | Head Of Intellectual Property | Leadership |
Jon Burgess | General Manager, Orlando | Leadership |
Evan Walker | Vice President Marketing | Leadership |
Emily Schimek | Sr. Director, Device Development | Leadership |
Jon Ellenthal | President | Leadership |
Laura Weidner | Head Of Corporate Development And Quality | Leadership |
14 more people are available in the full profile.
Complete people profiles for ApiJect
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ApiJect
3 dated milestones of ApiJect across 7 years, from founding to its latest funding, stage changes and deals.
- Founded ApiJect is founded.
- Funding First funding round of $590.0M.
- Funding Latest funding round, Series D, of $111.0M.
Competitors of ApiJect
ApiJect has 3 listed competitors in our database, 3 of them funded. They include Exela Pharma, August Bioservices and INCOG BioPharma Services.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| exelapharma.com | 2005 | Lenoir, United States | $7.09M | 247 | Sterile injectable pharmaceuticals are manufactured alongside CDMO services. | |
| augustbio.com | 2017 | Nashville, United States | $88.6M | 86 | Diversified research services for clinical solutions are offered. | |
| incogbiopharma.com | 2020 | United States | $86.63M | Injectable drug products are manufactured by this biopharma CDMO. |
Detailed competitors of ApiJect
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ApiJect
The website of ApiJect (apiject.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▼ 61.5% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as ApiJect (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Apiject
Complete news archive for ApiJect
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ApiJect
ApiJect was founded in 2015 and raised its 1st funding round 5 years after it was founded.
ApiJect is headquartered in Stamford, United States. It is registered at Stamford, Connecticut, United States.
Jay Walker is the CEO of ApiJect, as recorded in our data. They have also founded this company.
ApiJect is a funded company, having raised a total of $111M across 2 funding rounds to date. The company's 1st funding round was a Debt β Conventional of $590M, raised on Nov 2020.
ApiJect manufacturer of medicine injectors, focusing on providing healthcare solutions, biopharma outsourcing, cdmo, small molecules peptides, formulation, and injectibles. It serves clients with dedicated solutions, emphasizing quality, innovation, and sustainable growth in its core markets. It continues to evolve, meeting industry challenges with strategic approaches.
ApiJect's top competitors include Exela Pharma, August Bioservices and INCOG BioPharma Services.
ApiJect offers Blow-Fill-Seal Container, Apiject Platform, and Prefilled Injector.
ApiJect has 3 investors. Key investors include Royalty Pharma, Jefferies, and DFC.
ApiJect operates through Apiject Systems, Corp..
